Liu Ming, Gao Ya, Li Lun, Ge Long, Yao Liang, Chu Xiajing, Wu Fanqi, Tian Jinhui
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou city, China.
Department of Medical Data, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Cochrane Database Syst Rev. 2025 Apr 14;4(4):CD015888. doi: 10.1002/14651858.CD015888.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness and safety of anti-TIGIT inhibitors in combination with PD-1 inhibitors or PD-L1 inhibitors compared to treatment with PD-1 inhibitors or PD-L1 inhibitors in the first-line treatment of advanced NSCLC. To assess the effectiveness and safety of anti-TIGIT inhibitors in combination with chemotherapy and PD-1 inhibitors or PD-L1 inhibitors compared to treatment with chemotherapy plus PD-1 inhibitors or PD-L1 inhibitors in the first-line treatment of advanced NSCLC.
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估在晚期非小细胞肺癌一线治疗中，与单独使用程序性死亡受体1（PD-1）抑制剂或程序性死亡配体1（PD-L1）抑制剂相比，抗T细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域（TIGIT）抑制剂联合PD-1抑制剂或PD-L1抑制剂治疗的有效性和安全性。评估在晚期非小细胞肺癌一线治疗中，与化疗联合PD-1抑制剂或PD-L1抑制剂相比，抗TIGIT抑制剂联合化疗及PD-1抑制剂或PD-L1抑制剂治疗的有效性和安全性。
